269 related articles for article (PubMed ID: 7757987)
1. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
3. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
[TBL] [Abstract][Full Text] [Related]
4. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
[TBL] [Abstract][Full Text] [Related]
5. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol)-doxorubicin conjugates containing beta-lactamase-sensitive linkers.
Senter PD; Svensson HP; Schreiber GJ; Rodriguez JL; Vrudhula VM
Bioconjug Chem; 1995; 6(4):389-94. PubMed ID: 7578358
[TBL] [Abstract][Full Text] [Related]
7. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
8. Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates.
Vrudhula VM; Svensson HP; Senter PD
J Med Chem; 1997 Aug; 40(17):2788-92. PubMed ID: 9276025
[TBL] [Abstract][Full Text] [Related]
9. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
[TBL] [Abstract][Full Text] [Related]
10. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
11. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
12. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
[TBL] [Abstract][Full Text] [Related]
13. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.
Senter PD; Schreiber GJ; Hirschberg DL; Ashe SA; Hellström KE; Hellström I
Cancer Res; 1989 Nov; 49(21):5789-92. PubMed ID: 2790791
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
16. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
[TBL] [Abstract][Full Text] [Related]
17. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.
Vrudhula VM; Svensson HP; Kennedy KA; Senter PD; Wallace PM
Bioconjug Chem; 1993; 4(5):334-40. PubMed ID: 8274516
[TBL] [Abstract][Full Text] [Related]
19. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
20. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]